^
    Back
    Association details:
    Biomarker:MET amplification + MET Exon 14 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)

    Excerpt:
    ...Response rate to crizotinib in patients with ROS1 translocation or MET amplification or MET exon 14 mutation...
    Trial ID:
    METROS
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC.org
    Title:

    Crizotinib in Patients With MET-Amplified NSCLC

    Published date:
    03/03/2021
    Excerpt:
    A total of 88 patients...received crizotinib....MET amplification gene copy number greater than or equal to 6 was detected by next-generation sequencing in 15 of 19 (78.9%) analyzable patients. Of these 15 patients, objective responses were observed in six (40%), two of whom had concurrent MET exon 14 alterations.
    DOI:
    10.1016/j.jtho.2021.02.010